bazedoxifene has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Q; Liao, Y; Lin, W; Meng, Y; Wang, N; Wei, X | 1 |
| Bossen, J; Bruchhaus, I; Burkhardt, L; Fink, C; Heine, H; Mai, MM; Pfefferkorn, R; Roeder, T; Spohn, M; Steen, L; Uliczka, K | 1 |
2 other study(ies) available for bazedoxifene and Lung Neoplasms
| Article | Year |
|---|---|
Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer.
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mitochondria; NF-E2-Related Factor 2; Reactive Oxygen Species; Suppressor of Cytokine Signaling 3 Protein | 2023 |
An EGFR-Induced
Topics: Animals; Animals, Genetically Modified; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Synergism; ErbB Receptors; Gene Expression Profiling; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Trachea | 2019 |